Jefferies Financial Group Upgrades Pediatrix Medical Group (NYSE:MD) to Strong-Buy

Pediatrix Medical Group (NYSE:MD) was upgraded by equities research analysts at Jefferies Financial Group to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

A number of other research analysts have also recently commented on the stock. Truist Financial reduced their price target on shares of Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating on the stock in a research report on Thursday, February 19th. Zacks Research lowered shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. Deutsche Bank Aktiengesellschaft set a $19.00 target price on shares of Pediatrix Medical Group in a report on Friday, February 20th. Finally, UBS Group decreased their target price on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $19.80.

Pediatrix Medical Group Trading Up 0.6%

Shares of MD stock opened at $19.58 on Thursday. The business has a 50-day moving average price of $20.93 and a two-hundred day moving average price of $20.01. Pediatrix Medical Group has a 12-month low of $11.84 and a 12-month high of $24.99. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.66. The firm has a market cap of $1.63 billion, a P/E ratio of 10.09 and a beta of 0.79.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Thursday, February 19th. The company reported $0.50 EPS for the quarter, missing the consensus estimate of $0.53 by ($0.03). The firm had revenue of $493.77 million for the quarter, compared to the consensus estimate of $486.23 million. Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. Pediatrix Medical Group’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.51 earnings per share. Equities analysts anticipate that Pediatrix Medical Group will post 1.38 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pediatrix Medical Group news, CEO Mark S. Ordan sold 23,000 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $22.41, for a total value of $515,430.00. Following the sale, the chief executive officer owned 302,805 shares of the company’s stock, valued at $6,785,860.05. This trade represents a 7.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MD. Global Retirement Partners LLC lifted its holdings in Pediatrix Medical Group by 68,250.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock worth $29,000 after buying an additional 1,365 shares during the period. Transamerica Financial Advisors LLC purchased a new position in shares of Pediatrix Medical Group during the fourth quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Pediatrix Medical Group during the fourth quarter valued at approximately $33,000. Blue Trust Inc. bought a new position in shares of Pediatrix Medical Group during the fourth quarter valued at approximately $37,000. Finally, TD Private Client Wealth LLC bought a new position in shares of Pediatrix Medical Group during the fourth quarter valued at approximately $39,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.